Oncology Handbook
Interactive Reference
Home
Regimens
Color theme
Home
Regimens
Home
All Regimens
All Regimens
1935 regimens across all sites
Site
All
Ampullary
Anal
Biliary Cancers
Bladder Cancer
Bone Cancer
Breast Cancer
CNS Cancers
Cervical Cancer
Cutaneous Lymphoma
GIST
Gastric Cancer
HCC
Head and Neck
Hodgkin Lymphoma
Kaposi Sarcoma
Kidney Cancer
Lower GI Cancers
Lung Cancer (SCLC)
Melanoma
Merkel Cell Carcinoma
Multiple Myeloma
Neuroblastoma
Neuroendocrine Tumours
Occult Primary
Oesophageal Cancer
Ovarian Cancer
Pancreatic Cancer
Penile Cancer
Peritoneal Mesothelioma
Pleural Mesothelioma
Prostate Cancer
Sarcoma
Skin Cancers
Small Bowel Cancer
Testicular Cancer
Thymic Cancer
Thyroid Cancer
Uterine Cancer
Vaginal Cancer
Vulvar Cancer
Subsite
All
Adrenocortical Carcinoma
Adult Intracranial and Spinal Ependymoma
Adult Medulloblastoma
Advanced Kaposi sarcoma
Alveolar soft part sarcoma
Ampullary Adenocarcinoma
Anal canal cancer, locoregional disease
Anaplastic Thyroid Carcinoma
Angiosarcoma
Biliary tract cancers
Biomarker-based, TMB-H Tumors
Bladder
Breast Cancer with Brain Metastases
Breast, invasive, HER2-low
Breast, invasive, HER2-negative
Breast, invasive, HER2-positive
Breast, invasive, HER2-positive, low-risk T1N0
Breast, invasive, HER2-positive, node-positive
Breast, invasive, HR+
Breast, invasive, HR+/HER2- or HR-/HER2-
Breast, invasive, HR+/HER2-low
Breast, invasive, HR+/HER2-negative
Breast, invasive, HR+/HER2-negative or HER2-positive
Breast, invasive, HR+/HER2-positive
Breast, invasive, HR-/HER2-
Breast, invasive, any subtype
Breast, invasive, any subtype with bone metastases
Breast, invasive, inflammatory breast cancer
Breast, invasive, inflammatory breast cancer, HER2-positive
Breast, invasive, triple-negative
Carcinosarcoma
Cervix
Cholangiocarcinoma with NRG1 gene fusions
Chondrosarcoma, Conventional
Chondrosarcoma, Dedifferentiated
Chondrosarcoma, Metastatic and widespread disease
Chordoma
Circumscribed Glioma
Classic Hodgkin Lymphoma
Clear Cell Carcinoma of the Ovary
Clear cell histology
Combined hepatocellular carcinoma-cholangiocarcinoma
Dedifferentiated chordoma
Dedifferentiated liposarcoma
Dermatofibrosarcoma protuberans
Desmoid tumors
Differentiated Thyroid Cancer
Disseminated disease M1
Ductal Carcinoma In Situ
Epithelial Ovarian/Fallopian Tube/Primary Peritoneal Cancer
Epithelioid hemangioendothelioma
Epithelioid sarcoma
Esophageal and esophagogastric junction adenocarcinoma
Esophageal and esophagogastric junction adenocarcinoma and squamous cell carcinoma
Esophageal squamous cell carcinoma
Esophagogastric junction adenocarcinoma
Ethmoid sinus, Maxillary sinus
Ewing Sarcoma
Extrapulmonary Poorly Differentiated: Neuroendocrine Carcinoma/Large or Small Cell Carcinoma/Mixed Neuroendocrine-Non-Neuroendocrine Neoplasm
Extraskeletal myxoid chondrosarcoma
Extraskeletal osteosarcoma
Field Cancerization/Confluent Epidermal Dysplasia
GI tract well-differentiated Grade 1/2 NETs
GI tract, Lung/Thymus, and Pancreas well-differentiated Grade 1/2 NETs
Gastric and gastroesophageal junction adenocarcinoma
Gastroenteropancreatic NETs
Giant Cell Tumor of Bone
Glioblastoma
Hepatocellular carcinoma
High-Grade Glioma: Other
High-Risk Neuroblastoma
High-Volume M1 CSPC
IDH-Mutant Astrocytoma, WHO Grade 2
IDH-Mutant Astrocytoma, WHO Grade 3
IDH-Mutant Astrocytoma, WHO Grade 4
In-transit disease
Inflammatory myofibroblastic tumor
Inguinal lymph nodes
Inguinal/pelvic lymph nodes
Intermediate or poor-risk germ cell tumor
Intermediate-Risk Neuroblastoma
Intrahepatic cholangiocarcinoma or extrahepatic cholangiocarcinoma with FGFR fusions/rearrangements
Intrahepatic cholangiocarcinoma or extrahepatic cholangiocarcinoma with FGFR2 fusions/rearrangements
Intrahepatic cholangiocarcinoma or extrahepatic cholangiocarcinoma with IDH1 mutations
KSHV-Associated Inflammatory Cytokine Syndrome
Kaposi sarcoma
Kaposi sarcoma with immune reconstitution inflammatory syndrome
Leptomeningeal Metastases from Breast Cancer
Leptomeningeal Metastases from Melanoma
Leptomeningeal Metastases from NSCLC
Limited cutaneous Kaposi sarcoma
Locally Advanced CSCC, Metastatic
Locally Advanced CSCC, Recurrent, Metastatic
Locally Advanced CSCC, Regional Lymph Node Disease
Low-Grade Serous Carcinoma
Low-Grade Serous Carcinoma / Grade 1 Endometrioid Carcinoma
Low-Grade Serous Carcinoma / Sex Cord-Stromal Tumors
Low-Volume M1 CSPC, High-Volume M1 CSPC
Lung/Thymus well-differentiated NETs
Lymphomatoid Papulosis
M0 CSPC BCR2
M1 CRPC
MSI-H/dMMR Tumors
Malignant Germ Cell Tumors
Malignant Sex Cord-Stromal Tumors
Malignant perivascular epithelioid cell tumor
Medullary Thyroid Carcinoma
Melanoma with Brain Metastases
Melanoma: Cutaneous — BRAF V600 mutant metastatic melanoma with brain metastases
Melanoma: Cutaneous — BRAF V600 mutant metastatic melanoma, symptomatic brain metastases, untreated
Melanoma: Cutaneous — Melanoma brain metastases
Melanoma: Cutaneous — Oligometastatic melanoma
Melanoma: Cutaneous — Resected stage IV metastatic disease
Melanoma: Cutaneous — Resected stage IV metastatic disease with prior anti-PD-1 exposure
Melanoma: Cutaneous — Stage III
Melanoma: Cutaneous — Stage III resectable
Melanoma: Cutaneous — Stage III/IV resectable
Melanoma: Cutaneous — Stage III/IV resectable with prior anti-PD-1 exposure
Melanoma: Cutaneous — Unresectable stage III or Stage IV metastatic
Melanoma: Cutaneous — Unresectable stage III or Stage IV metastatic with brain metastases
Melanoma: Cutaneous — Unresectable stage III or Stage IV metastatic, BRAF V600 mutant
Melanoma: Cutaneous — Unresectable stage III or Stage IV metastatic, BRAF non-V600 mutations or BRAF gene fusion
Melanoma: Cutaneous — Unresectable stage III or Stage IV metastatic, KIT mutation positive
Melanoma: Cutaneous — Unresectable stage III or Stage IV metastatic, NRAS Q61 mutation positive
Melanoma: Cutaneous — Unresectable stage III or Stage IV metastatic, NTRK1/2/3 gene fusion positive
Melanoma: Cutaneous — Unresectable stage III or Stage IV metastatic, NTRK1/2/3 or ROS1 gene fusion positive
Melanoma: Cutaneous — Unresectable stage III or Stage IV metastatic, ROS1 gene fusion positive
Melanoma: Cutaneous — Unresectable stage III or Stage IV metastatic, previously treated
Melanoma: Cutaneous — Unresectable stage III or Stage IV metastatic, previously treated with anti-PD-1
Meningiomas
Metachronous Oligometastatic CSPC, Oligometastatic/oligoprogressive mCRPC
Metastatic anal cancer
Metastatic anal cancer with symptomatic primary
Metastatic germ cell tumor, good-risk
Metastatic uveal melanoma
Metastatic uveal melanoma, HLA-A*02:01-positive
Metastatic uveal melanoma, hepatic-dominant
Metastatic/recurrent penile cancer
Mucinous Carcinoma of the Ovary
Mucosal melanoma
Multiple myeloma
Mycosis Fungoides - Stage IA
Mycosis Fungoides - Stage IB
Mycosis Fungoides - Stage IIB
Mycosis Fungoides - Stage III
Mycosis Fungoides with Large-Cell Transformation
Mycosis Fungoides/Sézary Syndrome - Relapsed or Refractory Disease to Multiple Prior Therapies
Mycosis Fungoides/Sézary Syndrome - Relapsed/Refractory Disease
Mycosis Fungoides/Sézary Syndrome - Stage IIB-IV Disease Refractory to Multiple Prior Therapies
NF2-Related Schwannomatosis
NSCLC with Brain Metastases
Nasopharynx
Nodular Lymphocyte-Predominant Hodgkin Lymphoma
Non-clear cell histology
Non-pleomorphic rhabdomyosarcoma
Occult Primary, Adenocarcinoma or Carcinoma Not Otherwise Specified
Occult Primary, Squamous Cell Carcinoma
Oligodendroglioma
Oligodendroglioma / IDH-mutant Astrocytoma
Oncocytic Carcinoma
Oral cavity
Oral cavity, Oropharynx, Hypopharynx, Glottic larynx, Supraglottic larynx
Oral cavity, Oropharynx, Hypopharynx, Larynx
Oral cavity, Oropharynx, Hypopharynx, Larynx, Nasopharynx
Oropharynx
Osteosarcoma
Pancreas well-differentiated Grade 1/2 NETs
Pancreatic
Papillary Thyroid Carcinoma
Pathologic stage pN1 nonseminoma after RPLND
Patients receiving ADT
Penile cancer
Penis
Perianal cancer with inadequate margins after local excision
Perianal cancer, T1,N0 well or moderately differentiated or select T2,N0
Peritoneal Mesothelioma
Pheochromocytoma/Paraganglioma
Pleural Mesothelioma, Epithelioid
Primary CNS Lymphoma
Primary Cutaneous Anaplastic Large Cell Lymphoma
Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type
Primary Cutaneous Follicle Center Lymphoma
Primary Cutaneous Indolent T-Cell Lymphoproliferative Disorders
Primary Spinal Cord Tumors
Primary Spinal Cord Tumors / NF1-associated plexiform neurofibromas
Primary locally advanced MCC
Primary regional disease
Rectal cancer
Recurrent angiomyolipoma, lymphangioleiomyomatosis
Recurrent locally advanced MCC
Recurrent regional disease N+ or in-transit disease if curative surgery and curative RT not feasible
Refractory KSHV-Associated Inflammatory Cytokine Syndrome
Relapsed or refractory Kaposi sarcoma
Relapsed or refractory germ cell tumor
Relapsed or refractory germ cell tumor, after prior chemotherapy
Renal Cell Carcinoma with Brain Metastases
Renal medullary carcinoma
Resectable GIST
Resectable GIST with significant morbidity
Residual viable seminoma or nonseminoma after first-line chemotherapy
SSTR-Negative Disease of Well-Differentiated Grade 1/2 NETs
Salivary gland tumors
Satellitosis/In-Transit Metastasis
Small Bowel Adenocarcinoma, Adjuvant
Small Bowel Adenocarcinoma, Adjuvant/Neoadjuvant
Small Bowel Adenocarcinoma, Metastatic
Small Cell Carcinoma of the Ovary
Small Cell Lung Cancer with Brain Metastases
Small Cell/Neuroendocrine Prostate Cancer
Small cell lung cancer
Smoldering myeloma
Soft tissue sarcoma
Solid Tumors with Brain Metastases
Solitary fibrous tumor
Solitary plasmacytoma or solitary plasmacytoma with minimal marrow involvement
Stage I pure seminoma
Stage I pure seminoma, adjuvant
Stage II
Stage IIA/IIB pure seminoma
Subcutaneous Panniculitis-Like T-Cell Lymphoma
Sézary Syndrome
TMB-H
Tenosynovial giant cell tumor / pigmented villonodular synovitis
Thymic Carcinoma
Thymoma
Transplant-associated Kaposi sarcoma
Tuberous Sclerosis Complex
Unresectable, recurrent, or metastatic GIST
Upper Urinary Tract
Uterine
Vaginal Cancer
Various
Very-High-Risk CSCC with nodal and non-nodal features
Very-High-Risk CSCC, Locally Advanced CSCC
Von Hippel-Lindau
Vulvar Squamous Cell Carcinoma
Well-Differentiated Grade 3 NETs, favorable biology
Well-Differentiated Grade 3 NETs, unfavorable biology
Intent
All
Adjuvant
Neoadjuvant
First-line
Second-line+
Metastatic
Maintenance
Other
Line
All
Adjuvant/Neoadjuvant
First-line
Second-line
Third-line+
Any
Search
Reset
Site
Regimen
Setting
Modality
Drugs
Evidence
Category
No regimens match your filters
← Prev
Next →
Regimen Detail
Drugs
Drug
Dose
Route
Schedule
Trial Evidence
Trial
Phase
N
Primary Endpoint
OS
PFS/rPFS
ORR
Key Outcomes
Biomarkers
Marker
Requirement
Mandatory
Required
Optional
Notes